Table 3.
Clinical and Treatment Characteristics of PIMS Patients
| Characteristics, n (%) | PIMS, n = 56 |
|---|---|
| Diagnosis of SARS-CoV-2 | |
| Serology only | 26 (46%) |
| Serology + PCR | 6 (11%) |
| PCR only | 13 (23%) |
| No viral confirmation (contact with patient) | 11 (20%) |
| Clinical presentation | |
| Fever | 56 (100%) |
| Gastrointestinal symptoms | 46 (82%) |
| Cardiovascular | 34 (61%) |
| Rash | 32 (57%) |
| Respiratory | 22 (39%) |
| Conjunctivitis | 19 (34%) |
| Acute kidney injury | 11 (20%) |
| Neurologic | 11 (20%) |
| Laboratory | |
| Lymphopenia <2000 | 48 (86%) |
| ANC/LYM ratio ≥3.5 | 42/49 (86%) |
| Thrombocytopenia | 21 (38%) |
| CRP >6 mg/dL | 56 (100%) |
| Elevated ferritin | 32/35 (91%) |
| Elevated troponin (>25) | 13/35 (37%) |
| Albumin <3.5 | 27/42 (64%) |
| D-dimer checked; elevated | 38/47 (81%) |
| Elevated IL-6 | 3/8 (38%) |
| Echocardiography | |
| Pathologic/done | 32/40 (57%) |
| Treatment | |
| Steroids | 46 (82%) |
| IV-IG | 32 (57%) |
| Steroids and IV-IG | 28 (50%) |
| Antibiotics | 27 (48%) |
| Aspirin | 23 (41%) |
| Low-molecular-weight heparin | 14 (25%) |
| Plasmapheresis | 1 (2%) |
| Remdesivir | 1 (2%) |
| Infliximab | 1 (2%) |
Abbreviations: ANC/LYM, absolute neutrophil count/lymphocyte; IL-6, interleukin 6; IV-IG, intravenous immunoglobulin; PCR, polymerase chain reaction; PIMS, pediatric inflammatory multisystem syndrome PLT, platelet; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.